Objectives: To determine the prevalence of drug resistance mutations (DRM), the prevalence of drug susceptibility [transmitted drug resistance (TDR)] and the prevalence of HIV-1 variants among treatment-naive HIV-infected children in Manaus, Amazonas state, Brazil.
Introduction
In Brazil there are about 15 900 children under the age of 13 infected with HIV-1, 92.8% of whom have acquired HIV through mother-to-child transmission (MTCT). 1 The most recent estimate of HIV-1 prevalence in pregnant women is 0.4%. 2 The rate of MTCT is 3.6% in the country 3 and 6.6% in Amazonas state. 4 There is currently nationwide access to free combination ART. Although access to ART has expanded in recent years, only 61% of HIV-infected people that knew their HIV status were receiving it at the end of 2014. 5 The use of antiretrovirals for treatment in mothers and as prophylaxis in newborns for prevention of MTCT (PMTCT) can lead to selection of HIV drug resistance in infected infants and is likely to be the source of primary drug resistance in this population. [6] [7] [8] The threat of increased onward transmission of drug-resistant strains to newly infected individuals, i.e. primary drug resistance, has the potential to compromise the effectiveness of first-line ART regimens, [9] [10] [11] increasing the rate of viral failure or the length of first-line antiretroviral regimens. 12 Brazilian paediatric treatment guidelines recommend drug resistance testing in all treatmentnaive infants, children and adolescents to guide individual therapy choices. 13 Additionally, Brazilian treatment guidelines were updated in 2014 to recommend providing ART to all HIV-infected children below 12 months of age regardless of their CD4 cell count, and after that age following clinical and CD4 cell count criteria. As first-line treatment, children receive a regimen consisting of two NRTI plus either an NNRTI or a PI. 13 In Brazil, the prevalence of primary resistance has been estimated and reported to be very variable in children newly diagnosed with HIV. 14 The number of subjects analysed has been small, ranging from 10 to 55, with TDR rates from 0% to 19.2% for NNRTI, 0% to 11.5% for NRTI and 0% to 8% for PI. [15] [16] [17] [18] However, wider use of ART could result in increased primary resistance to NRTI and especially to NNRTI, as has been reported in high-income 11, 19 and low-income countries. 20 , 21 The genetic diversity in HIV-1 subtypes and recombinants might affect the emergence of resistance 22, 23 and has implications for resistance monitoring. In Brazil, there are reports of increasing HIV-1 genetic diversity in adults [24] [25] [26] as well as in children with multiple subtypes and 21.7% harbouring non-B subtypes. 27 Although the clinical significance of HIV drug resistance has been well documented in adult populations, there are few studies on the prevalence and patterns of drug resistance mutations (DRM) in paediatric HIV-infected populations.
14 Transmitted drug resistance (TDR) monitoring of paediatric HIV-1-infected populations is needed to optimize treatment success and preserve future treatment options. 28 The aim of this study was to describe the prevalence and profile of DRM, of TDR and of HIV-1 genetic variants among newly diagnosed, antiretroviral-naive children infected with HIV-1 in a paediatric HIV reference service centre in Manaus, Amazonas state, Brazil.
Methods

Study design and subjects
A retrospective cohort study was conducted at the reference HIV/AIDS paediatric service of Tropical Medicine Foundation Doctor Heitor Vieira Dourado (FMT-HVD) in the city of Manaus, Amazonas state, Brazil. This tertiary hospital is a reference centre that provides HIV care and services for PMTCT of HIV within the public health system and deals with the highest number of cases of HIV/AIDS in Amazonas state.
Eligible participants were children who attended the HIV/AIDS service from all age groups who were newly diagnosed with HIV, with perinatally acquired HIV infection, and ART naive. They were included if they had at least one available genotypic resistance profile between January 2010 and December 2015. Children with previous prophylactic use of antiretrovirals (zidovudine) for PMTCT were included. Children older than 2 years were mainly self-referrals brought in by parents or guardians, or referrals from other healthcare facilities. Diagnosis of HIV-1 infection was confirmed by positive HIV RNA in children aged less than 18 months and by two serial positive serological assays in children older than 18 months.
Data collection
A paediatrician extracted routine sociodemographic, clinical and laboratory data recorded in medical records and entered these into a database. Sociodemographic data included diagnosis age, sex and transmission mode. Clinical data included obstetric variables from the mother such as prenatal care and mode of delivery, timing of their HIV infection diagnosis, use of ART (beginning ART before or after becoming pregnant) and intrapartum prophylaxis, postnatal infant prophylaxis and breastfeeding. For recorded values of CD4 cell count and HIV RNA viral load, the most recent measurement before the date of enrolment was defined as the pretreatment count. CD4 cell counts were assessed with a FACSCalibur flow cytometer (Becton Dickinson Biosciences, San José, CA, USA) and viral loads with the NucliSens HIV-1 QT assay (bioMérieux, Boxtel, The Netherlands) until December 2010 and with the Abbott Real-Time PCR assay using m2000sp (Abbott Molecular Inc., Des Plaines, IL, USA) thereafter. Immunological category definition was based on CD4 count or percentage according to age, following Brazilian guidelines. 13 Children were classified into: no evidence of suppression; evidence of moderate suppression; or severe suppression. If the CD4! count and the CD4! percentage indicated different classification categories, the child was classified into the more severe category.
Genotypic analyses
HIV genotypic tests were run with a TrueGene TM kit (Siemens HealthCare Diagnostics, USA) and the quality of the test was ensured by using an external quality proficiency panel distributed by the Brazilian Ministry of Health. Resistance mutations were assigned by the Calibrated Population Resistance (CPR) algorithm, 29 which is based on the WHO DRM list for surveillance of transmitted HIV-1 drug resistance. 30 Additional analyses were conducted in order to verify pretreatment drug resistance, using the Stanford HIVdb Program, version 7.0 (Stanford University, Palo Alto, CA, USA). 31 To predict the effect of the identified DRM on drug susceptibility, sequences identified by the CPR algorithm were classified as susceptible 
Outcomes
The main outcomes of interest were the prevalence of HIV-1 subtype diversity, and the presence of DRM and TDR. The presence of sequences containing at least one DRM to any drug class (i.e. NRTI, NNRTI and PI) was considered to constitute DRM. The presence of mutations in two of these drug classes (NRTI ! NNRTI, NRTI ! PI or NNRTI ! PI) was considered double resistance, and triple resistance was the presence of DRM in all three classes. TDR was defined as the presence of mutations associated with any level of impaired drug susceptibility. Sequences identified by the CPR algorithm as having surveillance DRM (SDRM), but classified as susceptible or potentially low-level resistant by the HIVdb Program, were not considered resistant for transmitted resistance rate estimation. The presence of low-, intermediate-or high-level resistance was considered as resistance in our analysis. For PI, only major mutations were considered. In this analysis, major PI mutations were defined as those DRM with a score of 30 or more in the Stanford HIVdb Program. 32 In addition, the prevalence of any DRM was calculated using the WHO criteria from the pretreatment HIV drug resistance surveillance that is based on relevant antiretrovirals used in the country. 33 According to this definition, any HIV drug resistance is defined with respect to one or more of the following drugs or drug classes: nevirapine, efavirenz, any NRTI, darunavir/ritonavir, lopinavir/ritonavir or atazanavir/ritonavir. Sequences classified as low-, intermediate-or high-level resistant according to the Stanford HIVdb Program were aggregated as 'HIV drug resistant'.
Data analysis
The prevalence was expressed as a percentage with the 95% CI. Data were described using percentages, and medians with IQRs, as appropriate. The prevalence of any DRM, any DRM based on the WHO criteria and any TDR were also analysed in the sample of children ,18 months of age with genotype available between 2010 and 2015, as recommended by the WHO for surveillance of initial drug-resistant HIV-1 in children newly diagnosed with HIV. 34 Baseline characteristics were compared between those who had received PMTCT and those who had not, using the v 2 test (categorical Drug resistance in children in Amazonas JAC variables) and the Mann-Whitney U-test (continuous variables). Data were analysed using Stata SE 10.0 (StataCorp LP, College Station, TX, USA).
Ethics
The study was approved by the Ethical Institutional Review Board of FMT-HVD with waiver of consent (reference number 1.054.945).
Results
Study population selection
A total of 129 children infected with HIV-1 in the 2000-15 period were ART naive and eligible for inclusion in this study. Drug resistance was tested between 2010 and 2015 in 128 children (99.2%) (1 had no blood collected to perform the assay). Among those tested (n " 128), 122 had results available. Four samples were excluded due to unknown HIV transmission route and one due to sexual violence as the transmission route. Thus, 117 children (90.7%) were included in the analysis.
Characteristics of the sample
The characteristics of the study sample are shown in Table 1 .
Children were mainly female (60.7%), native residents of Manaus (94.0%) and the median age of the study sample when tested was 3.7 years (IQR " 0.9-7.9 years). Viral load measurements before treatment had a value of .50 000 copies/mL in 53.8% of the children and 73.5% of the children presented evidence of moderate or severe immunosuppression. Most children (64.3%) had a history of breastfeeding. Among the 117 children (Table 1) , 33 (28.2%) had been exposed to maternal and/or infant PMTCT. Only 16.2% of the mothers had been diagnosed with HIV before or during pregnancy. Among PMTCT-exposed children, 10 of the mothers (30.3%) had received antiretrovirals during pregnancy, 51.5% had a history of intrapartum prophylaxis with zidovudine and all children received postnatal infant prophylaxis with zidovudine.
Characteristics of HIV-1 variants
Most children had HIV-1 subtype B (80.2%), followed by 6.0% subtype C, and several unique recombinant forms [BF (4.3%), DB (4.3%) and F (3.4%)]. In addition, two children had other unique recombinant forms [BC (0.9%) and KC (0.9%)]. Table 2 shows all samples with detected DRM and specifies which ones were considered for TDR analysis. Twenty-five of the 117 patients had viruses with at least one mutation in genes associated with resistance to one or more drug families indicative of DRM. Thus, the overall DRM prevalence was 21.4% (95% CI " 13. 8-28.9) in this study population (Table 3) . That included 1.7% (95% CI " 0.6-4.0) resistance associated with NRTI, 19.7% (95% CI " 12.3-27.0) resistance associated with NNRTI and 1.7% (95% CI " 0.6-4.0) resistance associated with PI.
Prevalence of DRM in our cohort
Mutations were found in 22.6% of children with no previous PMTCT exposure and in 18.2% of those with PMTCT exposure (Table 3 ). The frequencies of mutations associated with resistance to PI and NRTI were higher in PMTCT-exposed children (3.0%) than in PMTCT-unexposed children (1.2%). Mutations associated with resistance to NNRTI were detected in 21.4% of children with no previous PMTCT and in 15 .2% of PMTCT-exposed children.
Dual-class DRM involving NRTI and NNRTI was observed only in two children (Table 3) . Of the 31 sequences that presented DRM, 20 sequences had a single drug mutation (64.5%) ( Table 4 ). The most common NNRTI mutation was E138A (37.0%; 10 out of 27 sequences), for NRTI the only DRM found was M184V (n " 2) and for PI the two DRM observed were M46IM (n " 1) and M46L (n " 1) (Figure 1) .
Among children ,18 months of age with genotype available between 2010 and 2015 (n " 39), the prevalence of any DRM was 20.5% (95% CI " 7.3-33.8) (Table S1 , available as Supplementary data at JAC Online). Among those ,18 months with no previous PMTCT exposure (n " 9), the prevalence of any DRM was 22.2% (95% CI " 11.7-56.1).
Prevalence of TDR in our cohort
Based on WHO criteria, six children presented with any DRM, resulting in a prevalence of 5.1% (95% CI " 1.1-9.2) ( Table 3) . Nineteen children harboured virus with TDR, i.e. presented mutations associated with any level of impaired drug susceptibility (Table 3) . Thus, global prevalence (i.e. to any antiretroviral drug class) was 16.2% (95% CI " 9.5-23.0). The prevalence of TDR for each of the available drugs was: 13.7% (95% CI " 7.4-20.0) for NNRTI, 1.7% (95% CI " 0.6-4.1) for NRTI and 3.4% (95% CI " 0.8-6.8) for PI. The prevalence of TDR was higher among PMTCT-exposed children than in PMTCT-unexposed children, overall and by drug class. However, the prevalence of TDR to any NNRTI in PMTCT-unexposed children (13.1%) was similar to that of PMTCT-exposed children (15.2%) (P: 0.77).
Among children ,18 months of age with genotype available between 2010 and 2015 (n " 39), the prevalence of any DRM based on WHO criteria was 5.1% (95% CI " 0.2-1.2) and the prevalence of any TDR was 20.5% (95% CI " 7.3-33.8) (Table S1 ).
Based on current Stanford drug-specificity in the classification of NNRTI mutations, 5 children were resistant to efavirenz (4.3%), 3 were resistant to etravirine (2.6%), 4 were resistant to nevirapine (3.4%) and 13 were resistant to rilpivirine (11.1%) mainly associated with the E138A mutation. Four children were resistant to the PI nelfinavir (3.4%) and two showed resistance to the NRTI lamivudine (1.7%). None of the patients showed resistance to relevant PI (darunavir/ritonavir, lopinavir/ritonavir or atazanavir/ritonavir). There was no association between PMTCT exposure and resistance to antiretrovirals (data not shown).
Discussion
The results of this study conducted among ART-naive children in Manaus, the capital of Amazonas state, indicate that a complex epidemic pattern is in place. Coupled with extensive prevalence of DRM and TDR, we observed unprecedented HIV-1 diversity characterized by the co-circulation of pure subtypes B, C and F, and diverse unique recombinant forms, including new mosaic sequences composed of subtypes such as D and K.
We found that the prevalence of DRM was high (21.4%) and overall our estimate was higher than rates reported in children and adolescent populations in Brazil, which range from 0% Drug resistance in children in Amazonas JAC to 12.8%. 16, 17, 27, 35, 36 However, studies from Bahia have reported a much higher prevalence of DRM in ART-naive children (27.0%-33.0%). 18, 37 Likewise, the prevalence of TDR was high, at 16.2%, which compromises future treatment options. This prevalence was comparatively higher than that in naive and treated HIV-infected children in Bahia. 37 An ART-naive children cohort in São Paulo, Brazil did not report any TDR. 27 As reported in some earlier studies, 38 the majority of patients with TDR had viruses with singleton mutations. The definition of any DRM based on the WHO criteria takes into consideration relevant DRM, i.e. those that affect antiretroviral drugs that are included in the national guidelines and commonly used in clinical practice. 34 The prevalence of any DRM with this criteria was 5.1% given that the mutation E138A, which greatly affects DRM prevalence, is not considered a relevant NNRTI, as rilpivirine is not used in clinical practice in Brazil in children. 13 The high prevalence of DRM in Manaus can be partly explained by the fact that suboptimal monotherapy with zidovudine for PMTCT was used in Brazil until 2007, 39 a regimen that is strongly associated with DRM development in women and transmission of drug-resistant virus to the children. 40 Thereafter, the Brazilian Ministry of Health guidelines recommended temporary triple-antiretroviral prophylaxis during pregnancy and delivery for those women not eligible for lifelong ART. 41, 42 This recommendation prevailed until the adoption of the intervention option B!, i.e. lifelong ART for all adult patients starting as soon as HIV is diagnosed Presents only T74S as a PI-selected accessory mutation that is polymorphic.
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regardless of the CD4 cell count at the end of 2013. 43 Temporary antiretroviral exposure associated with long-term universal distribution of antiretroviral drugs is known to favour selection of resistance mutations, which can compromise the effectiveness of antiretroviral prophylaxis for MTCT and future therapeutic options. 44 However, only 28.2% of the children in our study had been exposed to some form of PMTCT intervention. The high DRM presence found could also be due to suboptimal antiretroviral regimens in mothers for whom prophylaxis is not always well implemented.
NNRTI-associated mutations were predominant. Interestingly, NNRTI-associated mutations were observed in 21.4% of newly diagnosed, treatment-naive children with no reported or recorded PTMCT exposures. The finding of DRM among PMTCT-unexposed children suggests prior and unreported use of antiretrovirals or transmission of resistant viruses to these mothers. Thus, PMTCT could be an inadequate means of ruling out pretreatment drug resistance in our settings. The current WHO ART guidelines (2013) 45 recommend lopinavir-based regimens for all children ,3 years of age irrespective of PMTCT exposure. However, current Brazilian guidelines still have NNRTI-based regimens as one of the options for preferred first-line treatment for children. 13 In our study, 1.7% of treatment-naive children harboured viruses with resistance to two drug classes and 1.2% had not received PMTCT. Four other countries (Cameroon, Cuba, India and Spain) have reported naive paediatric subjects harbouring viruses with resistance to two drug classes. 14 The most common mutation was E138A and its prevalence (8.5%) was higher than that reported in other Brazilian (4.6%) 36 and international studies (up to 7.5%). 46 E138A occurs in up to 5% of ART-naive patients, depending on the virus subtype. 46 This mutation can be considered a natural polymorphism and may compromise new NNRTI such as rilpivirine or etravirine. Etravirine is currently available as a third-line option and is recommended only for adults in whom it is unlikely to cause viral suppression even with the use of darunavir/ritonavir or raltegravir. 47 In this situation drug activity may be limited due to class recycling. The most common NRTI drug mutation was M184V (1.7%), which confers resistance to lamivudine, emtricitabine and abacavir, but delays resistance to zidovudine and stavudine. 48, 49 As expected, the epidemic in this region was composed mainly of subtype B, which is in agreement with the predominance of HIV-1 subtype B infections in Brazil 27, 50 and in the rest of Latin America.
14 However, subtype C was the second most prevalent form of infection. In Brazil, subtype C prevails in the southern region, 51 although recent studies have shown an unexpectedly high prevalence in central western Brazil.
27,36,52 Subtype C was first described in Amazonas state in 2006, 53 and its analysis showed high similarity to sequences from the south of Brazil, suggesting that HIV subtype C might have disseminated to the north following a south to north gradient pattern. 53 Pure subtype F1 isolates had a lower prevalence than BF1 unique recombinant forms, suggesting the co-circulation of HIV-1 subtype B and subtype F1 in the Amazonas has likely favoured its inter-subtype recombination. 54 Drug resistance in children in Amazonas Profile of specific mutations (number) detected among newly diagnosed HIV-infected children, stratified by previous PMCTC exposure. The number of HIV sequences with the indicated mutations are shown in white bars for children exposed to PMTCT interventions (n " 33) and in black bars for children not exposed to PMTCT interventions (n " 84).
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Andrade et al. 56 Our results indicate that the epidemic in Amazonas is complex and diverse as they show that 10.3% of the children presented intersubtype recombinants. Subtype-associated variability has shown different impacts on disease progression 57 and on the rate of CD4 cell count decline. 58 HIV-1 subtype-specific variability can have implications for resistance development. 22, 23 This study has some limitations. The median age of children in our study was .2 years. This differs from the approach followed by WHO for HIV DRM surveys, recommending enrolment of children for whom the duration of HIV infection is ,18 months. 34 Some TDR mutations could revert in the oldest prenatally ART-naive infected children, 59 which might result in underestimation of their prevalence. In fact, the prevalence of any DRM was similar in the overall sample (n " 117) compared with the sample of children ,18 months of age (n " 39) (21.4% versus 20.5%, respectively). However, the prevalence of any TDR was lower in the overall sample than in children ,18 months (16.2% versus 20.5%, respectively) Nevertheless, we did not observe a significant trend of the prevalence of TDR with increasing age (children ,1 year old when tested " 18.6%, 1-5 years " 11.8% and 5 years " 17.7%; P value for trends " 0.98). Moreover, approx. 70% of children in our study were reportedly PMTCT unexposed, while this will be less likely to occur in more recent studies once adoption of option B ! , implemented in Brazil in 2013, 43 is more widespread. The potential inclusion of children with unreported ART exposure due to PMTCT or HIV treatment remains and should be considered a possible limitation of the study. We lack information about DRM in the mothers, so a possible association between the type of medication the mother was taking and the resistance patterns of their children cannot be evaluated. However, this study shows a high prevalence of DRM in children born to PMTCT-experienced mothers. Given the age group and PMTCT exposure, caution is warranted when comparing with other studies.
HIV-1 subtype showed a complex epidemic profile with expansion of subtype C. The diverse patterns of inter-subtype HIV-1 recombinants observed indicate a wide circulation of mosaic viruses in Amazonas state and highlight the need for surveillance of HIV-1 diversity in the region. Brazil is working to reduce perinatal infections in children. However, our data show that an extensive proportion of newly diagnosed HIV-infected infants and young children carry resistant viruses, in particular to NNRTI. Resistanceassociated mutations are also present in a considerable proportion of children with no reported or recorded antiretroviral drug exposures. Together, these data support the use of genotypic tests prior to ART initiation and, in line with WHO guidelines, 45 the updated HIV treatment guidelines regarding the use of PI as preferred antiretrovirals for first-line therapy (i.e. lopinavir/ritonavir-based first-line regimens) in HIV-infected infants and young children regardless of PMTCT history.
Brazil is currently considering the adoption of option B! for children and adolescents. In this new context, all children newly diagnosed with HIV would start ART immediately after HIV diagnosis, regardless of age, presence of symptoms, CD4 and viral load level. As part of the recommended clinical monitoring, a baseline resistance test in all HIV-positive children is already performed. At the national level, these data have the potential to provide strategic information for the assessment of ART-programme effectiveness, which may inform public health actions with immediate impact on the quality of treatment and care of children living with HIV.
This study shows how surveillance of HIV drug resistance may be performed using programmatic data in settings where HIV genotyping is available, recommended and performed in HIV-infected children through vertical transmission. These existing data could be used for surveillance purposes and have the potential to be expanded at the national level. HIV drug-resistance surveillance in Brazil is supported by a network of 22 reference laboratories (RENAGENO) that have the capacity to perform high-quality HIV genotyping, in order to provide reliable information. In addition, its information system (SISGENO) has been operating since 2007. 26 The surveillance plan could be based on a census of all cases that would improve representativeness.
Considering that Brazil presents a prevalence of vertical transmission of HIV higher than that in other parts of Latin America,
